Merck (MRK) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Futures extend losses after economic data
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen at multi-decade lows, dollar drops before US data
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- Meta Platforms, IBM, Caterpillar fall premarket; American Airlines, Chipotle rise
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Merck's (MRK) KEYTRUDA Receives FDA Breakthrough Designation
October 27, 2014 6:45 AM EDTMerck (NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of patients with Epidermal Growth Factor Receptor (EGFR) mutation-negative, and Anaplastic Lymphoma Kinase (ALK) rearrangement-negative non-small cell lung cancer (NSCLC) whose disease has progressed on or following platinum-based chemotherapy. This is the second Breakthrough Therapy Designation granted for KEYTRUDA.
The FDAs Breakthrough Therapy Designation of KEYTRUDA underscores that new treatment approaches for advanced non-small cell lung cancer continue to be needed, said Dr. Roger Perlmutter,... More
